Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions.

Therefore, under conditions of compromised renal perfusion, administration of etoricoxib may cause a reduction in prostaglandin formation and, secondarily, in renal blood flow, and thereby impair renal function. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.Etoricoxib is an inhibitor of human sulfotransferase activity, particularly SULT1E1, and has been shown to increase the serum concentrations of ethinyl estradiol. In a study evaluating the 60 mg dose compared to the 90 mg dose, etoricoxib 60 mg once daily and 90 mg once daily were both more effective than placebo. Etoricoxib(Arcoxia) generic Nucoxia (90 mg) is a non-steroidal anti-inflammatory drug (NSAID), prescribed for osteoarthritis, rheumatoid arthritis and gouty arthritis.

Arthritis; Asthma; Depression; Diabetes; Heart Disease; Herbals; Man's Health; Muscle Relaxant; Pain Relief; Sleep Aid; Weight Loss; Woman's Health; Allergies; Anxiety; Anti Viral ; Search.
Patients with a recent history of myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention within 6 months preceding enrollment were excluded. Patients enrolled in the Programme had a wide range of cardiovascular and gastrointestinal risk factors at baseline. The most frequently observed adverse experiences were consistent with the safety profile for etoricoxib (e.g. Some selective COX-2 inhibitors have been associated with an increased risk of skin reactions in patients with a history of any drug allergy. Been taking arcoxia 90 mg for about 10 months. Total number of patients randomised, n= 17,412 on etoricoxib and 17,289 on diclofenac. By continuing to browse the site you are agreeing to our policy on the use of cookies.

The rate of absorption was affected, resulting in a 36% decrease in CEtoricoxib is approximately 92% bound to human plasma protein over the range of concentrations of 0.05 to 5 µg/ml. Acute gout. • Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10). The onset of the effect of the medicinal product may be faster when ARCOXIA is administered without food. Therefore:The dose for RA and ankylosing spondylitis should not exceed 90 mg daily. 60 mg tablets: Dark green, apple-shaped, biconvex tablets debossed '200' on one side and 'ARCOXIA 60' on the other side.90 mg tablets: White, apple-shaped, biconvex tablets debossed '202' on one side and 'ARCOXIA 90' on the other side.120 mg tablets: Pale-green, apple-shaped, biconvex tablets debossed '204' on one side and 'ARCOXIA 120' on the other side.ARCOXIA is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis.ARCOXIA is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery.The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks (see sections 4.3, 4.4).As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. Studies with etoricoxib 30 mg once daily demonstrated efficacy superior to placebo over a 12 week treatment period (using similar assessments as the above studies).